Government-Owned Inventions; Availability for Licensing, 81555-81556 [2015-32879]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Center for Complex
Tissues (2016/05).
Date: February 15, 2016.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Bethesda, MD 20892,
(301)–451–3398, hayesj@mail.nih.gov.
Dated: December 23, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room # 3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for the
Development of Host-Targeted Therapeutics
to Limit Antimicrobial Resistance (R01).
Date: January 28–29, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
2H 200 A/B, 3F100, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Susana Mendez, DVM,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room 3G53B, National Institutes
of Health, NIAID, 5601 Fishers Lane Dr.,
MSC 9823, Bethesda, MD 20892–9823, (240)
669–5077, mendezs@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 23, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32769 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–32766 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Center for Scientific Review; Notice of
Closed Meeting
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: January 28, 2016.
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–14–
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
81555
092: Bioengineering Research Partnerships
(BRP).
Date: January 21, 2016.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Mehrdad Mohseni, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5211,
MSC 7854, Bethesda, MD 20892, 301–435–
0484, mohsenim@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 23, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32770 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute, Technology Transfer Center on
or before January 29, 2016 will be
considered.
SUMMARY:
Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
ADDRESSES:
E:\FR\FM\30DEN1.SGM
30DEN1
81556
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: A Novel FullyHuman Anti-CD30 Chimeric Antigen
Receptor for Treatment of CD30+
Lymphoma.
Description of Technology: Chimeric
antigen receptors (CARs) are hybrid
proteins that consist of two major
components: A targeting domain and a
signaling domain. The targeting domain
allows T cells which express the CAR to
selectively recognize and bind to
diseased cells that express a particular
protein. Once the diseased cell is bound
by the targeting domain of the CAR, the
signaling domain of the CAR activates
the T cell, thereby allowing it to kill the
diseased cell. This is a promising new
therapeutic approach known as
adoptive cell therapy (ACT).
Researchers at the National Cancer
Institute’s Experimental Transplantation
and Immunology Branch developed a
CAR that recognizes human tumor
necrosis factor receptor superfamily
member 8 (TNFRSF8, also known as
CD30). The expression of CD30 is
deregulated in a variety of human
cancers, including many lymphomas.
By creating a CAR that recognizes CD30,
it may be possible to treat these cancers
using adoptive cell therapy.
Potential Commercial Applications
—Treatment of human cancers
associated with expression of CD30 or
variants thereof
—Specific cancers include: NonHodgkins Lymphomas, Hodgkin’s
Lymphomas, several solid malignancies
mstockstill on DSK4VPTVN1PROD with NOTICES
Value Proposition
—Human components are less likely
to cause adverse or neutralizing immune
response in patients
—Targeted therapies decrease nonspecific killing of healthy cells and
tissues, resulting in fewer off-target sideeffects and healthier patients
Development Stage
In vivo/Lead Validation.
Inventor(s)
Jim N. Kochenderfer, M.D. (NCI).
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
Intellectual Property
HHS Reference No. E–001–2016/0–US–
01
US Provisional Application 62/241,896
(HHS Reference No. E–001–2016/0–
US–01) filed October 15, 2015 entitled
‘‘A Novel Fully-Human Anti-CD30
Chimeric Antigen Receptor for
Treatment of CD30+ Lymphoma’’
Licensing Opportunity: Researchers at
the NCI seek licensees for a chimeric
antigen receptor (CAR) that recognizes
human tumor necrosis factor receptor
superfamily member 8 (TNFRSF8, also
known as CD30) for use as a cancer
therapeutic.
Contact Information
Requests for copies of the patent
application or inquiries about licensing
and/or research collaboration and codevelopment opportunities should be
sent to John D. Hewes. Ph.D., email:
john.hewes@nih.gov.
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–32879 Filed 12–29–15; 8:45 am]
Institutes of Health, 7201 Wisconsin Avenue,
Suite 2c212, Bethesda, MD 20892, 301–402–
7705, JOHNSONJ9@NIA.NIH.GOV.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32773 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0014]
Agency Information Collection
Activities: Affidavit of Support, Form
I–134; Extension, Without Change, of a
Currently Approved Collection
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 60-day notice.
AGENCY:
BILLING CODE 4140–01–P
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration (USCIS) invites the general
public and other Federal agencies to
comment upon this proposed extension
of a currently approved collection of
information. In accordance with the
Paperwork Reduction Act (PRA) of
1995, the information collection notice
is published in the Federal Register to
obtain comments regarding the nature of
the information collection, the
categories of respondents, the estimated
burden (i.e. the time, effort, and
resources used by the respondents to
respond), the estimated cost to the
respondent, and the actual information
collection instruments.
DATES: Comments are encouraged and
will be accepted for 60 days until
February 29, 2016.
ADDRESSES: All submissions received
must include the OMB Control Number
1615–0014 in the subject box, the
agency name and Docket ID USCIS–
2006–0072. To avoid duplicate
submissions, please use only one of the
following methods to submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal Web site at
https://www.regulations.gov under
e-Docket ID number USCIS–2006–0072;
(2) Email. Submit comments to
USCISFRComment@uscis.dhs.gov;
(3) Mail. Submit written comments to
DHS, USCIS, Office of Policy and
Strategy, Chief, Regulatory Coordination
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Alzheimer’s
Center.
Date: February 4, 2016.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Jeannette L. Johnson,
Ph.D., National Institutes on Aging, National
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Pages 81555-81556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute, Technology Transfer
Center on or before January 29, 2016 will be considered.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD, 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be
[[Page 81556]]
obtained by contacting: Attn. Invention Development and Marketing Unit,
Technology Transfer Center, National Cancer Institute, 9609 Medical
Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702, Tel. 240-276-
5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential
Disclosure Agreement may be required to receive copies of the patent
applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: A Novel Fully-Human Anti-CD30 Chimeric Antigen
Receptor for Treatment of CD30+ Lymphoma.
Description of Technology: Chimeric antigen receptors (CARs) are
hybrid proteins that consist of two major components: A targeting
domain and a signaling domain. The targeting domain allows T cells
which express the CAR to selectively recognize and bind to diseased
cells that express a particular protein. Once the diseased cell is
bound by the targeting domain of the CAR, the signaling domain of the
CAR activates the T cell, thereby allowing it to kill the diseased
cell. This is a promising new therapeutic approach known as adoptive
cell therapy (ACT).
Researchers at the National Cancer Institute's Experimental
Transplantation and Immunology Branch developed a CAR that recognizes
human tumor necrosis factor receptor superfamily member 8 (TNFRSF8,
also known as CD30). The expression of CD30 is deregulated in a variety
of human cancers, including many lymphomas. By creating a CAR that
recognizes CD30, it may be possible to treat these cancers using
adoptive cell therapy.
Potential Commercial Applications
--Treatment of human cancers associated with expression of CD30 or
variants thereof
--Specific cancers include: Non-Hodgkins Lymphomas, Hodgkin's
Lymphomas, several solid malignancies
Value Proposition
--Human components are less likely to cause adverse or neutralizing
immune response in patients
--Targeted therapies decrease non-specific killing of healthy cells
and tissues, resulting in fewer off-target side-effects and healthier
patients
Development Stage
In vivo/Lead Validation.
Inventor(s)
Jim N. Kochenderfer, M.D. (NCI).
Intellectual Property
HHS Reference No. E-001-2016/0-US-01
US Provisional Application 62/241,896 (HHS Reference No. E-001-2016/0-
US-01) filed October 15, 2015 entitled ``A Novel Fully-Human Anti-CD30
Chimeric Antigen Receptor for Treatment of CD30+ Lymphoma''
Licensing Opportunity: Researchers at the NCI seek licensees for a
chimeric antigen receptor (CAR) that recognizes human tumor necrosis
factor receptor superfamily member 8 (TNFRSF8, also known as CD30) for
use as a cancer therapeutic.
Contact Information
Requests for copies of the patent application or inquiries about
licensing and/or research collaboration and co-development
opportunities should be sent to John D. Hewes. Ph.D., email:
john.hewes@nih.gov.
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2015-32879 Filed 12-29-15; 8:45 am]
BILLING CODE 4140-01-P
